July 1, 2019 – Biotronik announced the European market release of its new injectable cardiac monitor (ICM), Biomonitor III, following CE mark approval. The novel device is designed to help patients with irregular heart rhythms by documenting suspected arrhythmia or unexplained syncope with increased clarity.
As the most common type of arrhythmia, 33.5 million patients worldwide suffer from atrial fibrillation (AF).1 It is associated with a five-fold increase in risk of stroke, a three-fold increase in incidence of congestive heart failure and higher mortality.2 Aiming to improve the accuracy of arrhythmia detection and diagnosis, Biotronik’s new ICM offers increased signal quality.3
“What I like about Biomonitor III is the ease of use and the high signal fidelity,” said Associate Prof. Paul Gould, cardiologist and electrophysiologist at St Andrew’s War Memorial Hospital, Brisbane, Australia. “This coupled with the automatic Home Monitoring provides an excellent resource to establish a rhythm symptom correlation or to detect occult arrhythmias in my patients."
Biomonitor III’s BIOvector technology is designed to deliver high-definition signals. As a result, the high signal amplitudes and visibility of the p-waves3 make it easier for the physician to confidently evaluate arrhythmias.
Biotronik’s next-generation ICM is 60 percent smaller than its predecessor, BioMonitor 2, and comes ready to inject, with the device pre-assembled in a one-piece injection tool. To optimize patient comfort, Biomonitor III offers a very small size and flexible sensing antenna. The device is injected under the skin with a very small incision, facilitating in-office treatments.
The device works with Biotronik’s fully automated, ‘plug in and go’ Home Monitoring. Due to automatic pairing, initialization and data transmission, no active patient involvement is required. The new product also features Intelligent Memory Management, which prevents the overwriting of clinically relevant episodes. Thus, no relevant information is missed.
For more information: www.biotronik.com
2. Camm A.J. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–2747.
3. BIO|CONCEPT.BIOMONITOR III Study. Data on file.